Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease

European Journal of Nuclear Medicine and Molecular Imaging
Alexander DrzezgaEANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders

Abstract

To assess the clinical utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of early signs of neurodegeneration in conditions of increased risk for Alzheimer's disease (AD) as defined by: subjective cognitive decline (SCD), evidence of cerebral amyloid-pathology, apolipoprotein E (APOE) ε4-positive genotype, or autosomal dominant forms of AD (ADAD) in asymptomatic stages. A comprehensive literature search was conducted using the PICO model to extract evidence from relevant studies. An expert panel then voted using the Delphi method on three different diagnostic scenarios. The level of empirical study evidence for the use of FDG-PET to detect meaningful early signs of neurodegeneration was considered to be poor for ADAD and lacking for SCD and asymptomatic persons at risk, based on APOE ε4-positive genotype or cerebral amyloid pathology. Consequently, and consistent with current diagnostic criteria, panelists decided not to recommend routine clinical use of FDG-PET in these situations and to currently mainly reserve it for research purposes. Currently, there is limited evidence on which to base recommendations regarding the clinical routine use of FDG-PET to detect diagnostically meaningful earl...Continue Reading

References

Feb 11, 1992·Journal of the American Geriatrics Society·B H GuzeM E Phelps
Jan 1, 1995·Alzheimer Disease and Associated Disorders·A M KennedyR S Frackowiak
Dec 23, 2003·Proceedings of the National Academy of Sciences of the United States of America·Eric M ReimanJohn Hardy
Jun 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Eric M ReimanJohn Hardy
Jul 28, 2009·Journal of Clinical Epidemiology·David MoherUNKNOWN PRISMA Group
Oct 3, 2009·Neurobiology of Aging·Michael SchöllAgneta Nordberg
Nov 17, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·I UttnerC A F von Arnim
Jun 12, 2010·American Journal of Alzheimer's Disease and Other Dementias·Robert LaforceRémi W Bouchard
Jan 8, 2011·Alzheimer's Research & Therapy·Randall J BatemanChengjie Xiong
Feb 1, 2011·Annals of Neurology·Victor L VillemagneChristopher C Rowe
Nov 3, 2011·Psychiatry Research·Matthias L SchroeterOsama Sabri
Apr 21, 2012·Alzheimer Disease and Associated Disorders·Laure Saint-AubertJérémie Pariente
Jul 13, 2012·The New England Journal of Medicine·Randall J BatemanUNKNOWN Dominantly Inherited Alzheimer Network
Sep 11, 2012·European Journal of Nuclear Medicine and Molecular Imaging·Agneta NordbergKarl Herholz
Jan 18, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M A LeoneC L Bassetti
Mar 15, 2013·Neurology·Michael EwersUNKNOWN Alzheimer's Disease Neuroimaging Initiative (ADNI)
Oct 24, 2013·Journal of Alzheimer's Disease : JAD·Andrea BrugnoloFlavio Nobili
Nov 7, 2013·Proceedings of the National Academy of Sciences of the United States of America·Tammie L S BenzingerJohn C Morris
Nov 29, 2013·NeuroImage. Clinical·Michael EwersUNKNOWN Alzheimer's Disease Neuroimaging Initiative (ADNI)
Dec 4, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Agnese PiccoPatrizia Mecocci
Jan 15, 2014·Journal of Alzheimer's Disease : JAD·Simon Kang Seng TingJohn M Ringman
May 7, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Frank JessenUNKNOWN Subjective Cognitive Decline Initiative (SCD-I) Working Group
Dec 3, 2014·NeuroImage·N Maritza DowlingUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Mar 26, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Bruno DuboisUNKNOWN Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on “The Preclin
Aug 29, 2016·Journal of Alzheimer's Disease : JAD·Steffen WolfsgruberUNKNOWN AgeCoDe Study Group
Mar 21, 2017·Neurobiology of Aging·Valentina GaribottoUNKNOWN Geneva Task Force for the Roadmap of Alzheimer's Biomarkers

❮ Previous
Next ❯

Citations

Jun 23, 2018·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·F NobiliUNKNOWN EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders
May 8, 2018·European Journal of Nuclear Medicine and Molecular Imaging·Peter J NestorUNKNOWN EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders
May 2, 2018·European Journal of Nuclear Medicine and Molecular Imaging·Marina BoccardiUNKNOWN EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders
Apr 27, 2019·Frontiers in Endocrinology·Vincenzo TiganoUmberto Sabatini
Jul 5, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·J C RyuS O Yoon
May 21, 2018·European Journal of Nuclear Medicine and Molecular Imaging·Zuzana WalkerUNKNOWN EANM-EAN Task Force for the recommendation of FDG PET for Dementing Neurodegenerative Disorders
May 11, 2018·European Journal of Nuclear Medicine and Molecular Imaging·Femke BouwmanUNKNOWN EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders
Mar 7, 2021·International Journal of Molecular Sciences·Wieke M van Oostveen, Elizabeth C M de Lange
Mar 25, 2021·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Ming-Kai ChenRichard E Carson
Aug 3, 2021·Computational Intelligence and Neuroscience·Morteza AminiMahshad Ouchani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: Genetics

Alzheimer's disease is a neurodegenerative disease. Discover genetic and epigenetic aspects of Alzheimer’s disease, including genetic markers and genomic structural variations with this feed.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Related Papers

European Journal of Nuclear Medicine and Molecular Imaging
Peter NestorEANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders
European Journal of Nuclear Medicine and Molecular Imaging
Federica AgostaEANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders
American Journal of Alzheimer's Disease and Other Dementias
Xiaoyan SunDavid Bachman
European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
Flavio NobiliEANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders
© 2022 Meta ULC. All rights reserved